Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of doravirine versus darunavir/ritonavir in treatment-naive HIV-1 infection
2014-001127-69Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doravirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of subjects achieving HIV-1 RNA <50 copies/mL at Week 48. Started Nov 2014; status: completed.
02
Drugs
doravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-001127-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001127-69.